Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 149

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 149
---
,202420232022(in millions)U.S.RoWTotalU.S.RoWTotalU.S.RoWTotalHereditary Cancer$318.6 $45.9 $364.5 $280.5 $47.3 $327.8 $263.5 $42.0 $305.5 Tumor Profiling104.2 21.6 125.8 102.1 33.5 135.6 84.5 44.1 128.6 Prenatal176.5 0.6 177.1 150.6 0.7 151.3 115.6 0.8 116.4 Pharmacogenomics170.2 — 170.2 138.5 — 138.5 127.6 — 127.6 Autoimmune— — — — — — 0.3 — 0.3 Total revenue$769.5 $68.1 $837.6 $671.7 $81.5 $753.2 $591.5 $86.9 $678.4 Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and releasing the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of the Company’s performance to date.In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled.